Figure 7.

Efficacy of lamivudine treatment in “high-quality” studies or “low-quality” studies in interruption of mother-to-child transmission indicated by serum hepatitis B surface antigen or hepatitis B virus DNA of newborns. Vertical line indicates no difference between compared treatments. Horizontal lines show 95% CIs. Squares indicate point estimates, and the size of the squares indicates the weight of each study in the meta-analysis. CI: Confidence interval; HBV: Hepatitis B virus; M-H random: Mantel-Haenszel random-effects model; RR: Risk ratio; HBsAg: Hepatitis B surface antigen.